<p>Supplementary Figures and Table with legend arranged in a single presentable package</p>
<p>Effects of MRTX1133 in KPC/Y and subcutaneous models</p>
<p>MRTX1133 selectively inhibits KRASG12D and downstream MAPK signaling in vitro</p>
<p>MRTX1133 exerts in vivo effects early in treatment</p>
<p>MRTX1133 elicits changes in the tumor stroma and vasculature</p>
<p>MRTX1133 reduces metastatic burden in a tail vein model</p>
<p>KRASG12D inhibition alters the tumor immune microenvironment</p>
h-index: Number of publications with at least h citations each.